Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Szela Mary T, holds the title of CEO and President at TriSalus Life Sciences, Inc..
On 2026-11-18, the insider transacted 65,192 shares.The shares were transacted at a weighted average price of $2.46 per share, resulting in a total market-relevant value of $160K.
Szela Mary T (CEO and President) bought $160K of $TLSI
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.